SARcode And Sunesis Announce Start Of Phase 1 Clinical Trial In Ocular Inflammatory Diseases

 06.09.2008 04:12   medicalnewstoday.com

SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of a small molecule LFA-1 product candidate for T-cell mediated ophthalmic diseases.

World Eyesight Disorders